Cilostazol Discontinuation Guidelines

Absolute Contraindications Requiring Immediate Discontinuation

The American College of Cardiology recommends discontinuing cilostazol immediately in patients who develop congestive heart failure of any severity due to potential increased mortality risk related to its phosphodiesterase III inhibitor properties 1, 2, 3
Cilostazol is contraindicated in patients with hematologic abnormalities, such as thrombocytopenia or leukopenia progressing to agranulocytosis, as these conditions are reversible upon discontinuation 1, 2

The American College of Cardiology suggests considering discontinuation if patients experience persistent side effects, such as severe headache, despite dose reduction attempts 2
Common side effects that may warrant consideration for discontinuation include severe headache, occurring in up to 25% of patients 3

Evaluate patient tolerance at 2-4 weeks after initiation, and assess clinical benefit within 3-6 months to determine if long-term therapy will be beneficial 1
Approximately 20% of patients discontinue cilostazol within the first 3 months due to side effects, according to clinical practice data 1, 4

Reassess the risk-benefit of cilostazol if a patient develops new cardiac conditions 2

Regularly assess patients for development of heart failure symptoms, and consider discontinuation if no improvement in claudication symptoms is seen after 3-6 months of therapy 1, 2
Regularly reassess the benefit of cilostazol against its risks, including side effects and drug interactions 1, 2